PBYI
Puma Biotechnology, Inc.Healthcare · $467M market cap
Verdict
Share price
$9.51
close of Oct 3, 2026
Fair value
$3.67
Sticker Price
Payback Price
$1.47
buy price
PBYI is Overpriced: at $9.51 it trades 159% above its fair value of $3.67. Its buy price (Payback Price) is $1.47, 85% below today's price. Business quality is solid: 3 of 5 key numbers clear the 10% bar.
How we valued it
Free Cash Flow. Sales grew 0% a year over the last 3 years, below the 15% we look for in a fast grower, so we value it on its free cash flow instead of an earnings forecast.
Business quality
3 of 5 clear the 10% bar. What are the Big Five?
Follow PBYI
Get notified when it reaches its buy price of $1.47. Free.
Create a free accountSuperinvestors
None of the investors we track holds PBYI right now. In Q1 2026, 1 sold out. Who we track
Moves in Q1 2026
Sold out: Sarah Ketterer
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works